Processing

Please wait...

Settings

Settings

Goto Application

1. WO2000014110 - CRYSTALLINE FORMS OF EtO¿2?C-CH¿2?-($i(R))Cgl-Aze-Pab-OH

Publication Number WO/2000/014110
Publication Date 16.03.2000
International Application No. PCT/SE1999/001514
International Filing Date 02.09.1999
Chapter 2 Demand Filed 30.03.2000
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 5/065 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
065the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
C07K 5/0222
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
02containing at least one abnormal peptide link
022containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
0222with the first amino acid being heterocyclic, e.g. Pro, Trp
C07K 5/06026
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
06008with the first amino acid being neutral
06017and aliphatic
06026the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • EDVARDSSON, Daniel [SE]/[SE] (UsOnly)
  • HEDSTRÖM, Lena [SE]/[SE] (UsOnly)
  • LUNDBLAD, Anita [SE]/[SE] (UsOnly)
  • PETTERSSON, Ursula [SE]/[SE] (UsOnly)
Inventors
  • EDVARDSSON, Daniel
  • HEDSTRÖM, Lena
  • LUNDBLAD, Anita
  • PETTERSSON, Ursula
Agents
  • ASTRAZENECA AB
Priority Data
9802974-703.09.1998SE
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CRYSTALLINE FORMS OF EtO2C-CH2-($i(R))Cgl-Aze-Pab-OH
(FR) FORMES CRISTALLINES DE EtO2C-CH2-($i(R))Cgl-Aze-Pab-OH
Abstract
(EN)
There is provided EtO2C-CH2-($i(R))Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C-CH2-($i(R))Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
(FR)
L'invention concerne EtO2C-CH2-($i(R))Cgl-Aze-Pab-OH ou un de ses sels acceptables sur le plan pharmaceutique, sous une forme pratiquement cristalline. On a découvert que les formes cristallines de EtO2C-CH2-($i(R))Cgl-Aze-Pab-OH possèdent une stabilité chimique et une stabilité à l'état solide importantes par rapport à des formes amorphes du composé.
Latest bibliographic data on file with the International Bureau